1McGovern PG, Pankow JS, Shahar E, et al. Recent trends in acute coronary heart disease: mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. N Engl J Med, 1996,334:884-890.
2Sander C. Genomic medicine and the future of health care. Science, 2000,287:1977-1978.
5Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med,1990,323:1234-1238.
6Kuivenhoven JA, Jukema JW, Zwinderman AH, et al.The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med,1998,338:86-93.
7Maitland-van der Zee AH, Klungel OH, Stricker BH, et al. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors.Atherosclerosis,2002,163:213-222.
8Nikkari ST, O'Brien KD, Ferguson M, et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation, 1995,92:1393-1398.
9Humphries SE, Luong LA, Talmud PJ, et al. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial.Atherosclerosis, 1998,139:49-56.
10de Maat MP, Jukema JW, Ye S, et al. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol,1999, 83:852-856.
4Eiselt R,Domanski TL,Zibat A,et al. Identification and functional characterization of eight CYP3A4 protein variants [J]. Pharmacogenetic,2001,1(5):47.
5Sata F,Sapone A,Elizondo G,et al. CYP3A4 allelic variants with amino acid substitutions in axons 7 and 12:0 evidence for an allelic variant with altered catalytic activity[J]. Clin Pharmacol Ther ,000,67(1):8.
6Felix CA,Walker AH,Lange BJ,et al. Association of CYP3A4 genotype with treatment related leukemia [J]. Proc Natl Acad Sci USA,1998,5:3176.
7Harinder SM,Karen LG. Atorvastatin an updated review of its pharmacological properties and use in dyslipidaemia[J]. Drugs,2001,1(12):1835.
8Gonzalez F,Skoda RC,Kimura S,et al. Characterization of the common genetic defect in humans in debrisoquine metabolism [J].Nature,1988,31:442.
9Mulder AB,Van Lijf HJ,Bon MA,et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin [J]. Clin Pharmacol Ther,2001,0(6):546.
10Geisel J. The efficacy of simvastatin is not influenced by CYP2D6 polymorphism[J]. Clin Pharmacol Ther ,2002,0(11):95.
